Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BREO ELLIPTA vs PROAIR DIGIHALER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.
Beta2-adrenergic receptor agonist; stimulates adenylate cyclase, increasing cyclic AMP (c AMP) in bronchial smooth muscle, resulting in bronchodilation.
Maintenance treatment of chronic obstructive pulmonary disease (COPD) including chronic bronchitis and/or emphysema,Maintenance treatment of asthma in patients aged 18 years and older
FDA: Treatment or prevention of bronchospasm in patients with reversible obstructive airway disease (e.g., asthma),FDA: Prevention of exercise-induced bronchospasm
One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.
90 mcg (2 inhalations) via oral inhalation every 4-6 hours as needed for bronchospasm. For exercise-induced bronchospasm, 180 mcg (2 inhalations) 15 minutes before exercise.
Fluticasone furoate: 24 hours (supports once-daily dosing). Vilanterol: 11 hours (supports once-daily dosing).
Terminal elimination half-life of albuterol (active ingredient) is 3.8-5.0 hours; clinical context indicates drug is rapidly cleared with no significant accumulation
Fluticasone furoate: primarily metabolized by CYP3A4; Vilanterol: primarily metabolized by CYP3A4.
Primarily metabolized by conjugation (sulfation) in the gastrointestinal tract and liver; minor CYP450 metabolism.
Fluticasone furoate is eliminated primarily via fecal excretion (approximately 101% of an oral dose) due to biliary clearance, with minimal renal excretion (<1%). Vilanterol is eliminated via metabolism and subsequent renal (approximately 70% of an IV dose) and fecal (approximately 30% of an IV dose) excretion.
Renal: 60-70% of systemically absorbed dose excreted in urine as sulfate conjugate; biliary/fecal: minimal (approximately 10% unchanged); unchanged drug in urine: <2%
Fluticasone furoate: >99.8% (primarily albumin). Vilanterol: approximately 94% (albumin and alpha-1-acid glycoprotein).
Approximately 10% bound to plasma proteins (primarily albumin)
Fluticasone furoate: approximately 4.5 L/kg (extensive tissue distribution). Vilanterol: approximately 165 L (large Vd, extensive distribution).
Vd of albuterol is approximately 1.0-4.0 L/kg (mean 2.5 L/kg), indicating extensive distribution into tissues
Inhaled: Fluticasone furoate absolute bioavailability approximately 15% (lung deposition). Vilanterol absolute bioavailability approximately 27% (lung deposition). Oral bioavailability is negligible for both (<2% for fluticasone furoate, <5% for vilanterol).
Inhalation: mean absolute bioavailability from a metered-dose inhaler is approximately 7% of the administered dose, though systemic exposure varies with inhaler technique
No dosage adjustment required for renal impairment. However, use with caution in severe renal impairment due to potential for increased systemic exposure.
No dose adjustment required for renal impairment. Albuterol is primarily hepatically metabolized and renally excreted as metabolites; however, no specific GFR-based guidelines exist.
Child-Pugh Class A and B: No dosage adjustment recommended. Child-Pugh Class C: Contraindicated.
No specific dose adjustment recommended for hepatic impairment. Use with caution in severe hepatic impairment due to potential accumulation; monitor for adverse effects.
Indicated for children aged 5 years and older with asthma. For ages 5-11: one inhalation of 100 mcg/25 mcg once daily. For ages 12 and older: same as adult dosing.
Children 4-11 years: 90-180 mcg (1-2 inhalations) every 4-6 hours as needed. For exercise-induced bronchospasm: 90-180 mcg 15 minutes before exercise. Weight-based dosing not typically used; follow age-based guidelines.
No dose adjustment required for elderly patients. Use with caution due to increased risk of comorbidities and adverse effects.
No specific dose adjustment required. Use lowest effective dose due to potential increased sensitivity and comorbidities. Monitor for tachycardia, tremor, and hypertension.
Long-acting beta2-adrenergic agonists (LABAs) increase the risk of asthma-related death. Use only as additional therapy for patients not adequately controlled on a long-term asthma control medication or whose disease severity warrants initiation of both an inhaled corticosteroid and a LABA.
No FDA black box warning.
Increased risk of asthma-related death when used as monotherapy for asthma without inhaled corticosteroid,Candida infections of the mouth and pharynx,Pneumonia in patients with COPD,Adrenal insufficiency,Hypercorticism and adrenal suppression,Paradoxical bronchospasm,Hypersensitivity reactions including anaphylaxis,Cardiovascular effects like increased blood pressure and heart rate,Eosinophilic conditions,Reduced bone mineral density,Glaucoma and cataracts
Paradoxical bronchospasm with fatal outcomes; discontinue immediately if occurs,Life-threatening asthma exacerbations; need for increased use may indicate worsening asthma,Cardiovascular effects: increased heart rate, hypertension, arrhythmias; use with caution in patients with cardiovascular disorders,Hypokalemia and hyperglycemia; monitor serum potassium and glucose in susceptible patients,Rare anaphylactic reactions,Do not exceed recommended dose; excessive use may lead to death
Status asthmaticus or acute episodes of COPD requiring intensive therapy,Primary treatment of acute asthma exacerbation,Severe hypersensitivity to milk proteins or any ingredient
Hypersensitivity to albuterol or any component of the product
No specific food interactions reported. However, grapefruit juice may increase systemic exposure to fluticasone furoate via CYP3A4 inhibition; although clinical significance is low, avoid excessive grapefruit consumption. No dietary restrictions necessary.
No specific food-drug interactions are known for albuterol. However, caffeine-containing foods and beverages (coffee, tea, cola, energy drinks) may potentiate the stimulant effects (e.g., tachycardia, tremor). Hypokalemia may be potentiated by concurrent use of potassium-depleting diuretics or prolonged use. Avoid high-sulfite foods if a sulfite sensitivity is present, as these may trigger bronchospasm in some asthmatics.
Insufficient human data; based on animal studies, corticosteroids (fluticasone furoate) and LABA (vilanterol) show no major teratogenicity but may cause fetal growth restriction at high systemic exposures. Avoid in first trimester unless benefit outweighs risk; use lowest effective dose in later trimesters.
Albuterol sulfate, the active ingredient in PROAIR DIGIHALER, is generally considered low risk during pregnancy. Animal studies have shown no evidence of teratogenicity at clinically relevant doses. In humans, inhaled beta-agonists are not associated with an increased risk of major congenital malformations. However, maternal asthma exacerbations pose significant risks to the fetus, including preterm birth and low birth weight. Therefore, the benefit of controlled asthma outweighs the theoretical risks. First trimester exposure is not linked to increased malformation rates. Second and third trimester use is considered safe, with no known fetal toxicity at standard doses. No specific teratogenic risk profile by trimester is established.
No data on drug excretion in human milk; M/P ratio unknown. Corticosteroids and LABAs are expected to be present in low concentrations. Caution if breastfeeding, especially in preterm infants. Consider alternative therapies.
Albuterol is excreted into breast milk in small amounts. The milk-to-plasma (M/P) ratio is approximately 2.5, but the infant dose is estimated to be less than 1% of the maternal dose. Due to low oral bioavailability, significant infant exposure is unlikely. However, observe the infant for signs of beta-adrenergic stimulation (e.g., tachycardia, irritability). The benefit of maternal asthma control generally outweighs the minimal risk to the breastfed infant.
No specific dose adjustments required due to pregnancy-induced pharmacokinetic changes, but use lowest effective dose to maintain asthma control due to potential fetal risk.
Pharmacokinetic changes in pregnancy (increased plasma volume, renal clearance) may lead to lower serum concentrations of albuterol. However, clinical effectiveness typically remains sufficient. No routine dose adjustments are recommended; dosing should be guided by symptom control. In severe asthma exacerbations during pregnancy, higher doses or more frequent administration may be required. Monitor for maternal tachycardia and hypokalemia.
Breo Ellipta (fluticasone furoate/vilanterol) is an ICS/LABA combination indicated for maintenance treatment of COPD and asthma. It is not for acute bronchospasm. The ELLIPTA inhaler is a once-daily, dry powder inhaler; each actuation delivers a fixed dose. Rinse mouth with water after use without swallowing to reduce oral candidiasis. Monitor for pneumonia in COPD patients. In asthma, it is not indicated for patients under 18 years; for COPD, use only in patients with a history of exacerbations. Do not discontinue abruptly.
PROAIR DIGIHALER contains albuterol sulfate, a short-acting beta-2 agonist (SABA). It is indicated for the treatment or prevention of bronchospasm in patients aged 4 years and older with reversible obstructive airway disease, and for the prevention of exercise-induced bronchospasm (EIB). The device is breath-activated, requiring a low inspiratory flow rate (approx. 20 L/min) for optimal dose delivery. Shake well before each use. Priming is not needed for new inhalers if used within 2 weeks; if not used for more than 2 weeks, prime by releasing 1 test spray into the air. Rinse mouth with water after each use to reduce risk of oropharyngeal candidiasis. Avoid concomitant use of non-selective beta-blockers (e.g., propranolol) as they may antagonize bronchodilatory effects. Monitor for paradoxical bronchospasm, tachycardia, and hypokalemia. Not for acute severe asthma exacerbation requiring intensive care; use a nebulized SABA or IV bronchodilator instead.
Use exactly as prescribed; it is not a rescue inhaler for sudden breathing problems.,Rinse mouth with water after each dose without swallowing to prevent oral thrush.,Do not stop taking this medication without consulting your doctor; stopping can worsen breathing.,Tell your doctor if you have any signs of infection, pneumonia, or worsening breathing.,Store the inhaler at room temperature away from moisture and heat; keep it closed when not in use.
Use exactly as prescribed; do not exceed recommended doses.,Shake the inhaler well before each use.,Exhale fully, place mouthpiece between lips, inhale deeply and forcefully to activate the dose; hold breath for 10 seconds, then exhale slowly.,Rinse mouth with water after each use to prevent mouth and throat irritation.,Do not use if the inhaler has been dropped or damaged; check dose counter regularly.,Seek emergency medical attention if breathing problems worsen despite using this medication.,Avoid foods or beverages that may trigger asthma symptoms, such as sulfites (e.g., dried fruits, wine).,Avoid caffeine (coffee, tea, soda) as it may increase side effects like nervousness and rapid heartbeat.,Stay hydrated but avoid large amounts of cold water immediately before or after use.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BREO ELLIPTA vs PROAIR DIGIHALER, answered by our medical review team.
BREO ELLIPTA is a Corticosteroid/Beta-2 Agonist Combination that works by Combination of fluticasone furoate, a corticosteroid that binds to glucocorticoid receptors to inhibit inflammatory gene transcription, and vilanterol, a long-acting beta2-adrenergic agonist that activates adenylate cyclase leading to bronchodilation.. PROAIR DIGIHALER is a Beta-2 Agonist Bronchodilator that works by Beta2-adrenergic receptor agonist; stimulates adenylate cyclase, increasing cyclic AMP (c AMP) in bronchial smooth muscle, resulting in bronchodilation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BREO ELLIPTA and PROAIR DIGIHALER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BREO ELLIPTA is: One inhalation (100 mcg fluticasone furoate / 25 mcg vilanterol) once daily via oral inhalation.. The standard adult dose of PROAIR DIGIHALER is: 90 mcg (2 inhalations) via oral inhalation every 4-6 hours as needed for bronchospasm. For exercise-induced bronchospasm, 180 mcg (2 inhalations) 15 minutes before exercise.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between BREO ELLIPTA and PROAIR DIGIHALER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. BREO ELLIPTA is classified as Category C. Insufficient human data; based on animal studies, corticosteroids (fluticasone furoate) and LABA (vilanterol) show no major teratogenicity but may cause fetal growth restriction at. PROAIR DIGIHALER is classified as Category C. Albuterol sulfate, the active ingredient in PROAIR DIGIHALER, is generally considered low risk during pregnancy. Animal studies have shown no evidence of teratogenicity at clinical. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.